A Phase 3 trial to evaluate the safety and efficacy of Eculizumab in the treatment of relapsing NMO. Target population must be 18 years and older, have a confirmed diagnosis of relapsing NMO, and have an EDSS score less than or equal to 7.
A study to evaluate the safety and efficacy of Eculizumab in patients with relapsing NMO
The primary purpose of this study is to assess how effective eculizumab treatment is compared with placebo in relapsing NMO patients based on the time to first relapse and relapse risk reduction. Eligible patients will be randomized 2:1 to one of two treatment arms: 1) eculizumab infusion or 2) placebo ...